Lowering of lipoprotein(a) level under niacin treatment is dependent on apolipoprotein(a) phenotype

Atherosclerosis Supplements

Volumn 18, Issue , 2015, Pages 53-58

  Artemeva, N V ^a   Safarova, M S ^a   Ezhov, M V ^a   Afanasieva, O I ^a   Dmitrieva, O A ^a   Pokrovsky, S N ^a  

^a INSTITUTE OF EXPERIMENTAL CARDIOLOGY   (Russian Federation)

Author keywords

Apolipoprotein(a) phenotype; Lipoprotein(a); Niacin

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ANTIPLASMIN; APOLIPOPROTEIN A; BIOLOGICAL MARKER; C REACTIVE PROTEIN; FIBRINOLYTIC AGENT; HIGH DENSITY LIPOPROTEIN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR; ANTILIPEMIC AGENT;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DRUG DOSE INCREASE; FEMALE; HUMAN; IMMUNOBLOTTING; INFLAMMATION; MALE; MIDDLE AGED; MOLECULAR WEIGHT; PHENOTYPE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; BLOOD; DOWN REGULATION; HYPERLIPOPROTEINEMIAS; PATIENT SELECTION; PREDICTIVE VALUE; RUSSIAN FEDERATION; TIME FACTOR; TREATMENT OUTCOME;

ADULT; APOPROTEIN(A); BIOMARKERS; DOWN-REGULATION; HUMANS; HYPERLIPOPROTEINEMIAS; HYPOLIPIDEMIC AGENTS; LIPOPROTEIN(A); MALE; MIDDLE AGED; MOLECULAR WEIGHT; NIACIN; PATIENT SELECTION; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RUSSIA; TIME FACTORS; TREATMENT OUTCOME;

EID: 84928910656     PISSN: 15675688     EISSN: 18785050     Source Type: Journal    
DOI: 10.1016/j.atherosclerosissup.2015.02.008     Document Type: Article

References (15)

1. Utermann G., Menzel H.J., Kraft H.G., Duba H.C., Kemmler H.G., Seitz C. Lp(a) glycoprotein phenotypes: inheritance and relation to Lp(a)-lipoprotein concentrations in plasma. J Clin Invest 1987, 80:458-465.
2. Kronenberg F., Utermann G. Lipoprotein(a): resurrected by genetics. J Intern Med 2013, 273(1):6-30.
3. Erqou S., Thompson A., Di Angelantonio E., Saleheen D., Kaptoge S., Marcovina S., et al. Apolipoprotein(a) isoforms and the risk of vascular disease: systematic review of 40 studies involving 58,000 participants. J Am Coll Cardiol 2010, 55:2160-2167.
4. Kamstrup P.R., Tybjærg-Hansen A., Nordestgaard B.G. Extreme lipoprotein(a) levels and improved cardiovascular risk prediction. J Am Coll Cardiol 2013, 61:1146-1156.
5. Nordestgaard B.G., Chapman M.J., Ray K., Boren J., Andreotti F., Watts G.F., et al. European Atherosclerosis Society Consensus Panel. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J 2010, 31:2844-2853. European Atherosclerosis Society Consensus Panel.
6. Lavigne P.M., Karas R.H. The current state of niacin in cardiovascular disease prevention. J Am Coll Cardiol 2013, 61:440-446.
7. Kuvin J.T., Dave D.M., Sliney K.A., Mooney P., Patel A.R., Kimmelstiel C.D., et al. Effects of extended-release niacin on lipoprotein particle size, distribution, and inflammatory markers in patients with coronary artery disease. Am J Cardiol 2006, 98:743-745.
8. Julius U., Fisher S. Nicotinic acid as a lipid-modifying drug - a review. Atheroscler Suppl 2013, 14(1):7-13.
9. Ezhov M.V., Safarova M.S., Afanasieva O.I., Kukharchuk V.V., Pokrovsky S.N. Lipoprotein(a) level and apolipoprotein(a) phenotype as predictors of long-term cardiovascular outcomes after coronary artery bypass grafting. Atherosclerosis 2014, 235:477-482.
10. Safarova M.S., Trukhacheva E.P., Ezhov M.V., Afanasieva O.I., Afanasieva M.I., Tripoten M.I., et al. Pleiotropic effects of nicotinic acid therapy in men with coronary heart disease and elevated lipoprotein(a) levels. Kardiologiia 2011, 5:9-16. [RUS].
11. Bruckert E., Labreuche J., Amarenco P. Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis. Atherosclerosis 2010, 210:353-361.
12. The AIM-HIGH Investigators Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011, 365:2255-2267.
13. Albers J.J., Slee A., O'Brien K.D., Robinson J.G., Kashyap M.L., Kwiterovich P.O., et al. Relationship of apolipoproteins A-1 and B, and lipoprotein (a) to cardiovascular outcomes: the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes). J Am Coll Cardiol 2013, 62:1575-1579.
14. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J 2013, 34(17):1279-1291. HPS2-THRIVE Collaborative Group.
15. Cenarro A., Puzo J., Ferrando J., Mateo-Gallego R., Bea A.M., Calmarza P., et al. Effect of nicotinic acid/laropiprant in the lipoprotein(a) concentration with regard to baseline lipoprotein(a) concentration and LPA genotype. Metabolism 2013, 63(3):365-371.